source
- Merck's remigromig meets visual acuity goal in diabetic macular edema trial, safety signals notedMerck announced that its experimental eye drug remigromig achieved non‑inferiority to Roche’s Lucentis in a late‑stage trial for diabetic macular edema. The trial, called Brunello, measured visual…
- Indonesian court strikes down patent evergreening amendment, signaling pushback on drug pricing tacticsAn Indonesian Constitutional Court ruled that a recent amendment allowing patent evergreening was unconstitutional, reinstating the original restriction that balances patent rights with public heal…